Publicaciones en colaboración con investigadores/as de Medical University of Vienna (13)

2023

  1. APRIL: A double-blind, placebo-controlled, randomized, Phase Ib/IIa clinical study of ApTOLL for the treatment of acute ischemic stroke

    Frontiers in Neurology, Vol. 14

  2. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

2022

  1. Clinical trials in pediatric ALS: a TRICALS feasibility study

    Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 23, Núm. 7-8, pp. 481-488

  2. First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

    Molecular Therapy - Nucleic Acids, Vol. 28, pp. 124-135

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Assessing autophagy in archived tissue or how to capture autophagic flux from a tissue snapshot

    Biology, Vol. 9, Núm. 3

2017

  1. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells

    Oncotarget, Vol. 8, Núm. 7, pp. 11600-11613

2016

  1. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

    Autophagy

  2. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

    Autophagy, Vol. 12, Núm. 1, pp. 1-222

2015

  1. CDK6 as a key regulator of hematopoietic and leukemic stem cell activation

    Blood, Vol. 125, Núm. 1, pp. 90-101

  2. Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells

    International Journal of Cancer, Vol. 136, Núm. 9, pp. 2078-2090

2014

  1. Programming of neural cells by (endo)cannabinoids: From physiological rules to emerging therapies

    Nature Reviews Neuroscience, Vol. 15, Núm. 12, pp. 786-801

  2. The expression of cannabinoid receptor 1 is significantly increased in atopic patients

    Journal of Allergy and Clinical Immunology, Vol. 133, Núm. 3